The world dermatological market generated total sales revenues of over $20 Billion last year. Over the past few months there have been many M&A happening in this segment. Firstly the news was of GlaxoSmithKline acquisition of Stiefel Laboratories, for $2.9 billion in cash and secondly one of the major derma player Graceway pharmaceuticals a portfolio company of GTCR Golder Rauner has entered into an Acquisition and License Agreement with Pfizer by which the former will be acquiring worldwide commercial rights for three investigational dermatological molecules from Pfizer. Out of the three , two are used for treatment of oily skin and acne - an early stage Stearoyl CoA Desaturase 1 (SCD1) Inhibitor and a Cholesterol-Acyltransferase (ACAT) Inhibitor, both of which are in Phase II clinical trials and the last one is an Activin-Like Kinase 5 (ALK-5) Inhibitor, currently in early pre-clinical development stage.
Thursday, July 23, 2009
Derma Next target..........................
The world dermatological market generated total sales revenues of over $20 Billion last year. Over the past few months there have been many M&A happening in this segment. Firstly the news was of GlaxoSmithKline acquisition of Stiefel Laboratories, for $2.9 billion in cash and secondly one of the major derma player Graceway pharmaceuticals a portfolio company of GTCR Golder Rauner has entered into an Acquisition and License Agreement with Pfizer by which the former will be acquiring worldwide commercial rights for three investigational dermatological molecules from Pfizer. Out of the three , two are used for treatment of oily skin and acne - an early stage Stearoyl CoA Desaturase 1 (SCD1) Inhibitor and a Cholesterol-Acyltransferase (ACAT) Inhibitor, both of which are in Phase II clinical trials and the last one is an Activin-Like Kinase 5 (ALK-5) Inhibitor, currently in early pre-clinical development stage.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment